Shares of Adaptimmune have skyrocketed since the opening bell on Jan. 13. The stock closed up 200% Monday after the company announced positive results with its SPEAR-T cancer program and has continued to rise this morning after it struck a…
Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement
Gilead Sciences is boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases. Gilead, along with two venture capital groups, provided Kyverna Therapeutics with an infusion of $25 million and also struck a…
MorphoSys gets $750m from Incyte for anti-CD19 cancer drug
Incyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to therapies for blood cancers sold by Amgen, Novartis and Gilead Sciences. Incyte is paying $750 million upfront for the antibody – called…
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
– Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer – FDA submission based on data from TRITON clinical program in advanced prostate cancer – FDA has assigned PDUFA date of…
Charles River and Takeda Enter Multi-Year Drug Discovery Deal
Takeda Pharmaceutical has been on a tear over the past few weeks, striking deals to develop new therapies for various diseases. On Monday, the Japan-based pharma powerhouse announced a multi-year drug discovery deal with Charles River Laboratories. Charles River will…
GSK’s CEO Walmsley aiming for six new approvals in 2020
GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco with CNBC, Walmsley said there is a…
AbbVie’s Skyrizi Beats Out Novartis’ Cosentyx in Plaque Psoriasis
AbbVie reported that its Skyrizi met both primary and all ranked secondary endpoints in its Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis. The Phase III, multicenter, randomized, open-label, efficacy assessor-blinded, active-comparator trial studied the safety…
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion. The acquisition will allow Eli Lilly to expand its immunology pipeline with a late-stage…
Blueprint gets first approval as FDA backs stomach cancer drug
US biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for a certain kind of stomach cancer. The regulator approved Ayvakit (avapritinib) on the basis of high response rates seen in phase 1…
AI specialist Exscientia signs drug discovery tie-up with Bayer
UK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking to use its platform to find new cardiovascular and cancer drugs. Bayer is pledging up to €240 million ($266 million) in upfront…
